Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
09:05pm, Monday, 28'th Feb 2022 GlobeNewswire
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
07:08pm, Monday, 28'th Feb 2022
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead fo
Apellis Pharmaceuticals Q4 2021 Earnings Preview
10:35pm, Friday, 25'th Feb 2022 Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$1.60 (-272.0% Y/Y) and…
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
11:00pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Travere (TVTX) delivered earnings and revenue surprises of -16.67% and 1.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
12:55pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
09:15am, Thursday, 24'th Feb 2022
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
04:11pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.
Why Apellis (APLS) Might Surprise This Earnings Season
01:43pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Apellis (APLS) Might Surprise This Earnings Season
10:00am, Wednesday, 23'rd Feb 2022
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Situation Has Improved At Apellis Pharmaceuticals In Recent Months
06:29pm, Tuesday, 22'nd Feb 2022 Seeking AlphaThe Situation Has Improved At Apellis Pharmaceuticals In Recent Months
01:29pm, Tuesday, 22'nd Feb 2022
Apellis made a lot of progress in the last few months. The launch of Empaveli is progressing well and partner Sobi secured EMA approval for Aspaveli.
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
12:00pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ho
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results
07:00am, Tuesday, 22'nd Feb 2022
WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will hos
Avid (CDMO) to Report Q3 Earnings: What's in the Cards?
04:26pm, Monday, 21'st Feb 2022 Zacks Investment Research
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
